Compare
Seres Therapeutics, Inc. vs Elite Pharmaceuticals Inc vs Prelude Therapeutics Inc vs Whitehawk Therapeutics, Inc.
| Latest fiscal year | Seres Therapeutics, Inc. MCRBRevenue covers only part of its income (partial revenue) | Elite Pharmaceuticals Inc ELTP | Prelude Therapeutics Inc PRLD | Whitehawk Therapeutics, Inc. WHWK |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-03-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $148.87M | $12.14M | $7.14M |
| Revenue growth (YoY) | n/a | +77.1% | +73.4% | -72.5% |
| Gross margin | n/a | 50.4% | n/a | 89.4% (computed) |
| Operating margin | n/a | 33.0% | -861.3% | n/m |
| Net margin | n/a | 30.1% | -819.6% | -288.3% |
| Net income | $5.70M | $44.87M | -$99.50M | -$20.60M |
| EPS (Diluted) | $0.64 | $0.03 | -$1.29 | -$0.33 |
| Operating cash flow | $1.12M | $23.75M | -$56.30M | -$97.43M |
| Free cash flow | $865.0K | $22.82M | -$56.37M | -$97.98M |
| Cash & equivalents | $45.77M | n/a | $35.26M | $37.57M |
| Total assets | $138.19M | $138.29M | $141.31M | $150.83M |
| Total liabilities | $93.97M | $39.41M | $72.68M | $14.52M |
| Shareholders' equity | $44.22M | $98.88M | $68.64M | $136.31M |
| Return on year-end equity | 12.9% | 45.4% | -145.0% | -15.1% |
| Shares outstanding | 9.56M | 1.08B | n/a | 47.15M |
Revenue, most recent five fiscal years
| Fiscal year | Seres Therapeutics, Inc. | Elite Pharmaceuticals Inc | Prelude Therapeutics Inc | Whitehawk Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | n/a | $148.87M Ended 2026-03-31 | $12.14M Ended 2025-12-31 | $7.14M Ended 2025-12-31 |
| 1 year earlier | n/a | $84.04M Ended 2025-03-31 | $7.00M Ended 2024-12-31 | $25.98M Ended 2024-12-31 |
| 2 years earlier | n/a | $56.63M Ended 2024-03-31 | n/a | $24.35M Ended 2023-12-31 |
| 3 years earlier | n/a | $34.16M Ended 2023-03-31 | n/a | $15.22M Ended 2022-12-31 |
| 4 years earlier | n/a | $32.26M Ended 2022-03-31 | n/a | $14.00M Ended 2021-12-31 |